Primary prevention and research progress of venous thromboembolism in patients with cancer
10.3969/j.issn.1000-8179.2020.06.336
- VernacularTitle: 肿瘤患者静脉血栓栓塞症的一级预防及研究进展*
- Author:
Xu MA
1
Author Information
1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute
- Publication Type:Journal Article
- Keywords:
Cancer-associated venous thromboembolism;
Low molecular weight heparin;
New oral anticoagulants;
Onco-cardiology;
Thrombosis prevention
- From:
Chinese Journal of Clinical Oncology
2020;47(6):309-313
- CountryChina
- Language:Chinese
-
Abstract:
Cancer-associated venous thromboembolism (VTE) is a common complication and cause of death in patients with cancer. Therefore, strategies to prevent the occurrence of VTE have increasingly attracted attention. Prophylactic anticoagulant therapy can reduce the risk of VTE in patients with cancer. It is necessary to completely evaluate the benefits and potential adverse reactions and eliminate any contraindications of anticoagulant therapy before prophylactic anticoagulant therapy is administered to high-risk patients.
